CXCR Inhibitor

CXCR Inhibitors (64):

Cat. No.	Product Name	Effect	Purity

HY-15319

AMG 487	Inhibitor	99.80%
AMG 487 is an orally active and selective antagonist of CXC chemokine receptor 3 (CXCR3) which inhibits the binding of CXCL10 and CXCL11 to CXCR3 with IC₅₀s of 8.0 and 8.2 nM, respectively.

HY-15251

Reparixin	Inhibitor	99.99%
Reparixin is a non-competitive allosteric inhibitor of the chemokine receptors CXCR1 and CXCR2 activation with IC₅₀s of 1 and 100 nM, respectively.

HY-165428

SCH-900875	Inhibitor
SCH-900875 is an orally active, brain-penetrant and selective CXCR3 receptor inhibitor, which also shows high selectivity over CXCR1 and CXCR2 receptors. SCH-900875 binds to CXCR3, blocking the binding of ligands CXCL9, CXCL10, and CXCL11, inhibiting downstream G protein and β-arrestin signaling pathways to suppress inflammatory cell migration. SCH-900875 is promising for research of autoimmune diseases (rheumatoid arthritis, multiple sclerosis) and inflammatory disorders (psoriasis, inflammatory bowel disease).

HY-N0011

Baohuoside I	Inhibitor	99.94%
Baohuoside I, a flavonoid isolated from Epimedium koreanum Nakai, acts as an inhibitor of CXCR4, downregulates CXCR4 expression, induces apoptosis and shows anti-tumor activity.

HY-119339

SX-682	Inhibitor	99.67%
SX-682 is an orally bioavailable, potent allosteric inhibitor of CXCR1 and CXCR2. SX-682 can block tumor myeloid-derived suppressor cells (MDSCs) recruitment and enhance T cell activation and antitumor immunity.

HY-12488

LY2510924	Inhibitor	99.11%
LY2510924 is a potent and selective CXCR4 antagonist that blocks SDF-1 binding to CXCR4 with an IC₅₀ of 0.079 nM.

HY-15252

Reparixin L-lysine salt	Inhibitor	99.87%
Reparixin L-lysine salt is an allosteric inhibitor of chemokine receptor 1/2 (CXCR1/2) activation.

HY-P99190

Eldelumab	Inhibitor
Eldelumab (BMS-936557) is a human anti-CXCL10 (IP-10) monoclonal antibody (IgG1 type). Eldelumab selectively binds to CXCL10 and blocks CXCL10-induced calcium flux and cell migration. Eldelumab can be used in studies of autoimmune and auto-inflammatory diseases such as rheumatoid arthritis, ulcerative colitis and crohn's disease.

HY-P99404

Quetmolimab	Inhibitor	99.90%
Quetmolimab is a humanized anti-CX3CL1 monoclonal antibody. However, CX3CL1 is a chemokine with a modulating effect on chemotaxis and adhesion.

HY-101022

CXCR2-IN-1	Inhibitor	99.54%
CXCR2-IN-1 is a central nervous system penetrant CXCR2 antagonist with a pIC₅₀ of 9.3.

HY-P990254

Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173)	Inhibitor
Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) is an anti-mouse CXCR3/CD183 IgG monoclonal antibody. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) weakens the immune response by reducing the infiltration of CD4⁺ and CD8⁺ T cells. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) significantly prolongs the survival time of heart or islet transplants in mice. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) can be used for researches on immunology and cancer such as pancreatic cancer.

HY-P7061A

ALX 40-4C Trifluoroacetate	Inhibitor
ALX 40-4C Trifluoroacetate is a small peptide inhibitor of the chemokine receptor CXCR4, inhibits SDF-1 from binding CXCR4 with a K_i of 1 μM, and suppresses the replication of X4 strains of HIV-1; ALX 40-4C Trifluoroacetate also acts as an antagonist of the APJ receptor, with an IC₅₀ of 2.9 μM.

HY-163475

CXCL-CXCR1/2-IN-1	Inhibitor	99.64%
CXCL-CXCR1/2-IN-1 is an orally active ELR⁺CXCL-CXCR1/2 pathway inhibitor with an EC₅₀ of 42.7 nM for CXCR2. CXCL-CXCR1/2-IN-1 shows anticancer and antiangiogenic effects.

HY-P990255

Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5)	Inhibitor
Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) is an anti-mouse CXCL9/MIG IgG monoclonal antibody. Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) can reduce tumor infiltration of CD8⁺ cytotoxic T cells (CTLs). Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) can prolong the survival of transplanted hearts. Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) can be used for researches on immunology and cancer such as prostate cancer.

HY-160041A

Olaptesed pegol sodium	Inhibitor
Olaptesed pegol sodium A pegylated-based L-oligoribonucleotide aptamer targeting CXCL12. Olaptesed pegol sodium neutralizes CXCL12, and CXCL12 inhibition mobilizes chronic lymphocytic leukemia cells into the circulation and prevents their homing into the protective microenvironment.

HY-P10552

pCXCL8-1aa	Inhibitor	98.13%
pCXCL8-1aa is an anti-inflammatory peptide. pCXCL8-1aa competitively inhibits the binding of CXCL8 to glycosaminoglycans such as heparin sulfate (HS) by binding with high affinity. This reduces the presentation of CXCL8 on the surface of vascular endothelial cells, thereby inhibiting neutrophil migration and inflammatory responses. pCXCL8-1aa can be used to study inflammatory diseases such as rheumatoid arthritis.

HY-149096

CCR7 antagonist 1	Inhibitor	99.55%
CCR7 antagonist 1 (30c) is a dual CXCR2 (IC₅₀ of 11.02 μM) and CCR7 (IC₅₀ of 0.43 μM) antagonist.

HY-N3255

Minecoside	Inhibitor	99.86%
Minecoside is a CXCR4/STAT3 inhibitor with anticancer and anti-inflammatory activity. Minecoside decreases CXCR4 expression and suppresses STAT3 activation, thus to inhibit CXCL 12-induced invasion. Minecoside potently inhibits cancer metastasis and promotes apoptotic progression.

HY-RS03400

CXCR2 Human Pre-designed siRNA Set A	Inhibitor
CXCR2 Human Pre-designed siRNA Set A contains three designed siRNAs for CXCR2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-162632

Hit 14	Inhibitor	≥99.0%
Hit 14 is an inhibitor for C-X-C chemokine receptor type 4 (CXCR4) with IC₅₀ of 254 nM. Hit 14 inhibits the migration and invasion of cell MDA-MB-231. Hit 14 inhibits the Akt phosphorylation, exhibits anti-inflammatory activity, and ameliorateds the ear swelling and damage in mouse models.

Name
Email *

	Sorry, but the email address you supplied was invalid.